Fol News

Tutti gli approfondimenti
Tutte le notizie

Vbiv..-56% dopo fase 3 positiva...boh

Si aspetta sempre la news....
 
short sempre altissimo!!
Al 31 dicembre ancora in aumento del 10% a quasi 46 mil.
Le motivazioni: Poca fiducia nel titolo oppure volontà di tenere i prezzi compressi per raccogliere azioni!!
 
Iniziò a preoccuparmi, sui siti molti analisti dicono di vendere
 
ti diro che a me nn dispiace rispetto al resto degli escrementi che ho in ptf :D
 
Adesso che inizia a salire la criticate
Aspettate dategli fiducia
 
Good news! :yes:

VBI Vaccines (NASDAQ:VBIV) jumps 9% premarket in reaction to the announcement that results from a Phase 4 study of prophylactic 3-antigen hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier.

The study was designed to evaluate the immunogenicity of VBI’s 3-antigen HBV vaccine in support of the qualification of the batch as a new reference standard for vaccine release to the Israeli market, where its available as Sci-B-Vac.
The reference batch should elicit, a seroprotection rate (SPR) of at least 95% in young and healthy adult participants.

In this open-label, single-arm Phase 4 study in 91 healthy adults age 20-40 years, this objective was achieved two months after the second dose – the SPR at month 3 was 98.8%.
High-responder SPR was 81.4% and 97.6% at month 3 (after 2 doses) and month 7 (after 3 doses), respectively.

The geometric mean concentration of anti-HBs titers were also substantially above the protective threshold at 413.6 mIU/mL and 6799.9 mIU/mL at month 3 and month 7, respectively.
Anti-HBs titers were maintained above 2000 mIU/mL at month 12, suggesting a potent and sustained response.

Consistent with other clinical data, VBI’s 3-antigen HBV vaccine was well-tolerated with no safety signals observed.
 
Grecale ci aiuto con un grafico? Io ho 3,93 come prox resistenza
 
Si i dati sono davvero ottimi
 
Devi accedere o registrarti per poter rispondere.
Indietro